Predictive Oncology Inc (POAI)

[PENNIEStoSTACKS]

SKLN ~ OS 11,578,385, PATENTED, FDA APPROVED
https://www.otcmarkets.com/stock/SKLN/profile

Case Study > Huntingdon Valley Surgery Center
http://www.skylinemedical.com/wp-content/uploads/STREAMWAY_CaseStudy_HuntingdonValleySC.pdf

FDA
https://www.accessdata.fda.gov/cdrh_docs/pdf9/K090759.pdf
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K090759

PATENT
https://encrypted.google.com/patents/EP1060752A1?cl=da

“Helomics’ D-CHIP™ platform uses Big Data ( https://en.wikipedia.org/wiki/Big_data ) , AI ( https://en.wikipedia.org/wiki/Artificial_intelligence ) and bioinformatics ( https://en.wikipedia.org/wiki/Bioinformatics ) to provide actionable insights on cancer in the area of precision medicine. The D-CHIP platform generates revenues from subscriptions from Pharma, BioPharma and Diagnostic Companies, as well as service revenues from additional “molecular informatics” solutions that further analyze the data in D-CHIP™. Forming a joint venture will allow us to further build out the database of patient data and ramp up commercial activities.”

http://investors.skylinemedical.com/news-releases/news-release-details/skyline-medical-and-helomics-corporation-sign-joint-venture-term

“Our strategic growth plan is to invest in, and partner with, leading edge players in emerging areas of the healthcare industry to secure additional income streams and grow the value of Skyline,” Dr. Carl Schwartz, CEO of Skyline Medical, commented. “Helomics’ ability to offer data collection, analysis and actionable insights to BioPharma companies as they develop new cancer treatments, positions it as a highly-valuable partner to the fast-growing precision medicine sector. We are pleased to expand our relationship with Helomics through this investment and look forward to helping Helomics’ management to further commercialize its offering.”

Gerald Vardzel, CEO of Helomics, commented, “Precise analysis of cancer tumors can deliver invaluable insights for cancer diagnostics and aid in the development of targeted cancer therapies. Our advanced D-CHIP platform interprets correlations between the molecular and demographic profiles as well as the drug responses of the patient’s tumor. These actionable insights drive biomarker discovery and validation offering a unique opportunity for pharmaceutical and diagnostic companies to push the frontiers of medical knowledge and to advance innovation in healthcare. Our database contains profiles of approximately 149,000 cancer tumors, compiled from over a decade of clinical testing. We plan to use this investment to further leverage our high-value big data and bioinformatics solutions to enable healthcare and biopharma companies to develop revolutionary cancer treatment options.” http://investors.skylinemedical.com/news-releases/news-release-details/skyline-medical-acquiring-25-equity-stake-helomics-corporation

"Helomics® Corporation Announces the appointment of Dr. Marc Malandro to its Advisory Board, providing strategic insights for the Skyline Medical – Helomics Joint Venture"

Marc Malandro PhD, CLP, RTTP, currently Vice President of Operations for Science at the Chan Zuckerberg Initiative, to its Advisory Board. The addition of Dr. Malandro provides significant scientific and business expertise to Helomics as well as Helomics’ recently announced joint venture with Skyline Medical Inc (NASDAQ:SKLN) to build-out and commercialize the Helomics D-CHIP™ platform

http://investors.skylinemedical.com/news-releases/news-release-details/helomicsr-corporation-announces-appointment-dr-marc-malandro-its

Chan Zuckerberg Initiative
https://www.facebook.com/chanzuckerberginitiative/videos/849701948512778
https://www.facebook.com/chanzuckerberginitiative/videos/931048783711427

LISTEN TO THIS INTERVIEW
https://audioboom.com/posts/6478086-ceo-gerald-vardzel-of-helomics-corporation